Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease
International Journal of CardiologyPublished 1 August 2002
Enver Atalar, Ferhan Özmen, İbrahim C. Haznedaroğlu, Tayfun Açıl, Necla Özer, Kenan Övünç
Citations32
SJR quartileQ1
SJR score1.13
SNIP0.96
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The results suggest that lipid lowering with atorvastatin therapy significantly increases GFC, decreases fibrinogen levels, and causes leukocyte deactivation, and may, in part, explain the early decrease in cardiovascular events observed in clinical trials of statins.
Abstract
These results suggest that lipid lowering with atorvastatin therapy significantly increases GFC, decreases fibrinogen levels, and causes leukocyte deactivation. Our findings also suggest that atorvastatin treatment mitigates apoptosis of VSMC in the atherosclerotic plaque. These effects of atorvastatin may, in part, explain the early decrease in cardiovascular events observed in clinical trials of statins.
Keywords
Medicine
New England Journal of MedicinePrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
7,453 Citations1995James Shepherd, Stuart M. Cobbe +6 more
Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.
ScienceProtection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule
1,124 Citations1994Jianhua Cheng, Tong Zhou +6 more
Levels of soluble Fas were elevated in patients with systemic lupus erythematosus, and mice injected with soluble Fas displayed autoimmune features.
JAMAAntiatherothrombotic Properties of Statins
953 Citations1998Robert S. Rosenson, Christy Tangney
Experimental animal models suggest that statins may foster stability through a reduction in macrophages and cholesterol ester content and an increase in volume of collagen and smooth muscle cells, which help to explain the early and significant cardiovascular event reduction reported in several clinical trials of statin therapy.
The LancetStatins do more than just lower cholesterol
702 Citations1996Carl J. Vaughan, Michael Murphy +1 more
The hypothesis that drugs that lower plasma cholesterol concentration are of benefit to patients with coronary artery disease is supported, however, the clinical benefit of the drugs used in these studies is manifest early in the course of lipidlowering therapy before plaque regression could occur.
Annals of Internal MedicineCoronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)
640 Citations1993David H. Blankenhorn, Stanley P. Azen +10 more
In the Cholesterol Lowering Atherosclerosis Study (CLAS), it was shown that diet in conjunction with colestipol and niacin therapy had a beneficial effect on coronary artery lesions at 2 and 4 years based on the global change score [5, 15] and at 2 yearsbased on quantitative coronary angiography [16]; CLAS was the only angiographic trial to have used both the findings of quantitative coronaryAngiography and theglobal change score as end points.
Journal of the American College of CardiologyThe evolving role of statins in the management of atherosclerosis
574 Citations2000Carl J. Vaughan, Antonio M. Gotto +1 more
Clinical and experimental evidence indicates that the beneficial actions of statins occur rapidly and yield potentially clinically important anti-ischemic effects as early as one month after commencement of therapy.
Arteriosclerosis Thrombosis and Vascular BiologyHMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages
510 Citations1998Stefano Bellosta, D P Via +5 more
Data indicate an inhibition of MMP-9 secretion by the drug, mediated by the inhibition of synthesis of mevalonate, a precursor of numerous derivatives essential for several cellular functions.
CirculationHyperlipidemia and Coronary Disease
442 Citations1995Lucie Lacoste, Jules Y.T. Lam +4 more
Cholesterol lowering may reduce the risk of acute coronary events in part by reducing the thrombogenic risk, and hypercholesterolemia is associated with an enhanced platelet thrombus formation on an injured artery, increasing the propensity for acuteThrombosis.
Journal of the American College of CardiologyHMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
422 Citations1998Carmen Bustos, Miguel Ángel Hernández-Presa +7 more
In a rabbit atherosclerosis model, atorvastatin diminishes the neointimal inflammation, and this could contribute to the stabilization of the atherosclerotic plaque and the reduction of acute ischemic events in patients treated with statins.
Journal of the American College of CardiologyPravastatin Has Cholesterol-Lowering Independent Effects on the Artery Wall of Atherosclerotic Monkeys
349 Citations1998J. Koudy Williams, Galina K. Sukhova +2 more
Compared with control monkeys, the arteries of pravastatin-treated monkeys had better dilator function and plaque characteristics more consistent with plaque stability than those of monkeys not receiving pravastsatin.
Circulationβ Fibrinogen Gene Polymorphisms Are Associated With Plasma Fibrinogen and Coronary Artery Disease in Patients With Myocardial Infarction
290 Citations1996Isabelle Behague, Odette Poirier +9 more
The association with CAD appears to be the consequence of an increased risk of MI in subjects with severe CAD who carry the predisposing beta fibrinogen genotypes.
BloodSoluble cytokine receptors
276 Citations1996ML Heaney, DW Golde
The mechanisms by which soluble receptors are generated, the regulation of soluble receptor expression, the ways that soluble receptors modify receptor-ligand interactions, and how soluble receptors may impact on clinical medicine are discussed.
Arteriosclerosis Thrombosis and Vascular BiologyFas Is Expressed in Human Atherosclerotic Intima and Promotes Apoptosis of Cytokine-Primed Human Vascular Smooth Muscle Cells
266 Citations1997Yong‐Jian Geng, Lynne E. Henderson +3 more
Activation of the Fas death-signaling pathway contributes to the induction of SMC apoptosis during atherogenesis and furnish a mechanism whereby immune cells and their cytokines promote this cell death process related to vascular remodeling and plaque rupture.
Journal of the American College of CardiologySimvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
209 Citations2000Domenico Ferro, Sandro Parrotto +3 more
This study suggests that simvastatin possesses anti-inflammatory activity via the inhibition of pro-inflammatory cytokines TNF and IL-1beta expressed by monocytes.
Arteriosclerosis Thrombosis and Vascular BiologyEffects of Fluvastatin on Leukocyte–Endothelial Cell Adhesion in Hypercholesterolemic Rats
191 Citations1997Masaaki Kimura, Iwao Kurose +2 more
Journal of the American College of CardiologyPravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile
181 Citations1999George Dangas, Juan J. Badimón +8 more
Pravastatin therapy significantly decreased thrombus formation and improved the fibrinolytic profile in patients with and without CAD.
AtherosclerosisThe role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions
139 Citations1997Weijun Cai, Bruno Devaux +2 more
The data suggests that Fas/APO 1 regulated apoptosis is involved in the development of advanced human atherosclerotic lesions and that it probably determines the amount of tissue mass in the diseased vessels.
Arteriosclerosis Thrombosis and Vascular BiologySeasonal Variations of Rheological and Hemostatic Parameters and Acute-Phase Reactants in Young, Healthy Subjects
100 Citations1997Margit Fröhlich, M. Sund +5 more
Seasonal variations in rheological and hemostatic parameters investigated do not support the hypothesis that increased morbidity and mortality from cardiovascular diseases during winter may be mainly attributable to increased synthesis of acute-phase proteins due to infections.
The LancetEffect of atorvastatin on plasma fibrinogen
94 Citations1998Anthony S. Wierzbicki, P Lumb +2 more
The American Journal of CardiologyEffect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
82 Citations2000Carlos A. Dujovne, William S. Harris +3 more
Atorvastatin 80 mg/day produced marked reductions in serum low-density lipoprotein cholesterol, very low density lipop protein cholesterol, and triglycerides levels, and significant changes in plasma viscosity as well as other hemorheologic-hemostatic parameters, but no changes in Plasma fibrinogen levels.
Baillière s Clinical Haematology8 Control of plasma fibrinogen levels
40 Citations1989Fiona Green, Steve E. Humphries
It may be possible to develop DNA tests to identify individuals who, on the basis of their genotype, are at high risk of ischaemic heart disease and once identified, the subsequent risk of these individuals can be reduced by modifying life-style or by drug therapy to reduce other known risk factors such as cholesterol levels.
Fibrinolysis & proteolysis/Fibrinolysis and proteolysisUp-regulation of plasminogen activator inhibitor 2 (PAI-2) in response to α-lactalbumin
24 Citations1999Heather Ritchie, E. Schulte +1 more
An up-regulation of PAI-2 synthesis is reported following treatment of U937 cells with LEH and purified α-lactalbumin and it is reported that the effect was both dose- and time-dependent.
Clinical Drug InvestigationEffect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia
22 Citations1998Vasilios G. Athyros, Athanasios A. Papageorgiou +3 more
AtorVastatin in equipotent doses to simvastatin appeared to be more effective than the latter in reducing triglyceride and plasma fibrinogen in patients with hypercholesterolaemia, mainly in those with Frederickson’s phenotype IIb.
The American Journal of CardiologyFibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia
15 Citations2001Anthony S. Wierzbicki, P Lumb +2 more
The clinical and biochemical determinants of the fibrinogen response to simvastatin or atorvastsatin therapy were assessed in patients with severe polygenic or familial hypercholesterolemia treated in a randomized open-trial format design.